secwatch.observer — SEC 8-K summary
======================================

Issuer:     SeaStar Medical Holding Corp (ICU)
CIK:        0001831868
Form:       8-K
Filed at:   2025-09-24T23:59:59+00:00
Accession:  0001193125-25-215608
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SeaStar Medical DSMB recommends continue NEUTRALIZE-AKI trial; enrollment target raised to 339
--------------------------------------------------------------------------------

- DSMB reports zero device-related safety issues in first 100 patients; recommends continuation of pivotal AKI trial.
- Enrollment target increased from 200 to 339 patients to meet statistical power; 137 patients enrolled to date.
- Estimated enrollment completion near end of 2026 based on current rate and new site additions.
- QUELIMMUNE pediatric registry shows 75% 28-day survival and no device-related safety events in first 20 patients.
- Company highlights potential clinical benefit signal; plans to manage capital to support milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831868/000119312525215608/0001193125-25-215608-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831868/000119312525215608/icu-20250924.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-215608

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer